Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical Oncology Annual Meeting: the AMPLITUDE trial.
Alicia Morgans, MD, MPH, genitourinary medical oncologist at Dana-Farber Cancer Center in Boston, Massachusetts, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical Oncology Annual Meeting: the AMPLITUDE trial (NCT04497844).
This phase 3 study investigated adding the PARP inhibitor niraparib (Akeega) to abiraterone acetate and prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair (HRR) gene alterations.
Morgans highlights that for these patients, the combination of niraparib and abiraterone significantly improved radiographic progression-free survival compared to AAP alone. This represents a substantial 37% reduction in the risk of radiographic progression or death for patients with HRR gene alterations.
Transcription:
0:10 | There were many things at ASCO this year that were potentially practice-changing and really exciting. I think that there were multiple drugs that were presented in early phases of development that look really potentially beneficial and appear to have a relatively low [adverse event] burden that are quite exciting. But one of the studies that really was a notable one was the AMPLITUDE trial that included patients with HRR mutations in the metastatic hormone-sensitive prostate cancer setting. For those patients who received niraparib and abiraterone, they seem to have improved radiographic progression-free survival vs patients receiving just abiraterone.
0:52 | Of course, everyone is getting ADT as the backbone there, and with that, our rPFS prolongation, we saw that this may be an opportunity to treat this particularly poor prognosis population with something that can meaningfully shift the disease trajectory. I am hopeful to see further data that will update us over time, as well as to see what happens with the regulatory review process, because this patient population certainly needs more attention and needs options, and if this one is going to help them maintain that disease control and potentially even live longer on further data cuts, I think it will be important.